0.5522

3.99% +0.0212

After Hours: .5694 0.0172 +3.11%

Orgenesis Inc (ORGS)

Overview News Price History Option Chain Financials Why ORGS Down? Discussions Forecast Stock Split

Orgenesis Inc stock is currently priced at $0.5522, with a 24-hour trading volume of 57,622. It has seen a +3.99% increased in the last 24 hours and a +8.51% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.538 pivot point. If it approaches the $0.6011 resistance level, significant changes may occur.

Previous Close:

$0.531

Open:

$0.54

24h Volume:

57,622

Market Cap:

$18.98M

Revenue:

$27.75M

Net Income/Loss:

$-25.07M

P/E Ratio:

-1.0619

EPS:

-0.52

Net Cash Flow:

$-32.64M

1W Performance:

-4.79%

1M Performance:

+8.51%

6M Performance:

+14.80%

1Y Performance:

-51.98%

1D Range:

$0.531

$0.5799

52W Range:

$0.25

$1.50

Orgenesis Inc Stock (ORGS) Company Profile

Name

Orgenesis Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

480 659 6404

Address

20271 Goldenrod Lane, Germantown, MD

Employee

151

Twitter

Next Earnings Date

2024-06-07

Latest SEC Filings

ORGS's Discussions on Twitter

Orgenesis Inc Stock (ORGS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-18	Initiated	Dawson James	Buy

Orgenesis Inc Stock (ORGS) Latest News

Orgenesis prices 1.41M shares at 78c in registered direct offering - TipRanks.com - TipRanks

TipRanks

Proactive news headlines including Plurilock Security, Adastra Labs Holdings, BMEX Gold, Renforth Resources and ... - The Globe and Mail

The Globe and Mail

Orgenesis CEO to Participate in Webinar Panel on “New Approaches to COVID-19” on Thursday, September 10th - The Globe and Mail

The Globe and Mail

Proactive news headlines including Power Reit, Delta 9 Cannabis, Bragg Gaming and Acasti Pharma - The Globe and Mail

The Globe and Mail

Orgenesis Provides Year End Business Update

GlobeNewswire Inc.

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

GlobeNewswire Inc.

Orgenesis Inc Stock (ORGS) Financials Data

Orgenesis Inc (ORGS) Revenue 2024

ORGS reported a revenue (TTM) of $27.75 million for the quarter ending September 30, 2023, a -5.26% decline year-over-year.

Orgenesis Inc (ORGS) Net Income 2024

ORGS net income (TTM) was -$25.07 million for the quarter ending September 30, 2023, a -58.57% decrease year-over-year.

Orgenesis Inc (ORGS) Cash Flow 2024

ORGS recorded a free cash flow (TTM) of -$32.64 million for the quarter ending September 30, 2023, a -16.13% decrease year-over-year.

Orgenesis Inc (ORGS) Earnings per Share 2024

ORGS earnings per share (TTM) was -$0.90 for the quarter ending September 30, 2023, a -42.86% decline year-over-year.

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.